P1.10-01 Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)

Based on the findings of the PACIFIC trial, durvalumab as consolidation therapy is the standard-of-care for patients with unresectable Stage III NSCLC and no disease progression following chemoradiotherapy (CRT; the PACIFIC regimen). However, further improvements in outcomes are needed for this population and, to build upon the backbone of PD-L1 inhibition with durvalumab, immunotherapy combinations including anti-TIGIT, anti-CD73, and anti-NKG2a mAbs are now being explored. Two potential candidates, oleclumab and monalizumab, have demonstrated encouraging clinical activity in a phase 2 study when combined with durvalumab in this setting.